Qiagen updates draw analyst attention, shares react on NYSE and Xetra

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:38.

Qiagen (NL0015002SN0) sits firmly on investors' radar this week as fresh analyst commentary from Morgan Stanley and DZ Bank shapes expectations, while the shares trade both on the NYSE under the QGEN ticker and in euros on Xetra. Consensus numbers for the diagnostics specialist remain constructive despite a weak share-price performance over the past twelve months.

What the latest analyst calls say

Morgan Stanley recently upgraded Qiagen from Equal Weight to Overweight, lifting the price target to 42 US dollars from 40 dollars, citing signs of a growth inflection in the core business. The bank highlights improving demand trends in molecular diagnostics and consumables after a post-pandemic normalization phase.

DZ Bank also takes a constructive stance and assigns a Buy rating to Qiagen, pointing to an average analyst target around 43.96 dollars, which implies a double-digit percentage upside versus the latest US close. MarketScreener data show a spread of roughly 21 percent between the last closing price of 36.28 dollars and this average target.

How the consensus picture looks

On the German side, data compiled by wallstreet-online show an average price target of 50.14 euros from seven analysts, more than 50 percent above the current Xetra level near 32.5 euros. The same compilation places the lowest target at 46 euros and the highest at 59 euros, illustrating a broad but clearly positive expectation range.

Performance metrics underline the gap between cautious share pricing and constructive research views: over the past year Qiagen shares are down about 18 percent, while the stock has gained roughly 5.6 percent in the last 30 days and about 2.5 percent in June alone. The shares currently trade more than 30 percent below their 52-week high but over 16 percent above the 52-week low.

The business behind the targets

Qiagen generates most of its revenue with sample preparation technologies, molecular diagnostic tests and consumables used by clinical labs, pharmaceutical companies and research institutions worldwide. The company offers platforms for automated workflows and companion diagnostics that benefit from rising test volumes and precision-medicine initiatives.

Where the shares trade today

The Qiagen shares (NL0015002SN0) last traded on Xetra at about 32.51 euros on 2026-06-23, while the NYSE listing under the ticker QGEN changed hands around 37.28 US dollars on the same day.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.